Papers
Topics
Authors
Recent
Detailed Answer
Quick Answer
Concise responses based on abstracts only
Detailed Answer
Well-researched responses based on abstracts and relevant paper content.
Custom Instructions Pro
Preferences or requirements that you'd like Emergent Mind to consider when generating responses
Gemini 2.5 Flash
Gemini 2.5 Flash 48 tok/s
Gemini 2.5 Pro 48 tok/s Pro
GPT-5 Medium 26 tok/s Pro
GPT-5 High 19 tok/s Pro
GPT-4o 107 tok/s Pro
Kimi K2 205 tok/s Pro
GPT OSS 120B 473 tok/s Pro
Claude Sonnet 4 37 tok/s Pro
2000 character limit reached

SECRETS: Subject-Efficient Clinical Randomized Controlled Trials using Synthetic Intervention (2305.05078v1)

Published 8 May 2023 in eess.SP, cs.LG, stat.AP, and stat.ME

Abstract: The randomized controlled trial (RCT) is the gold standard for estimating the average treatment effect (ATE) of a medical intervention but requires 100s-1000s of subjects, making it expensive and difficult to implement. While a cross-over trial can reduce sample size requirements by measuring the treatment effect per individual, it is only applicable to chronic conditions and interventions whose effects dissipate rapidly. Another approach is to replace or augment data collected from an RCT with external data from prospective studies or prior RCTs, but it is vulnerable to confounders in the external or augmented data. We propose to simulate the cross-over trial to overcome its practical limitations while exploiting its strengths. We propose a novel framework, SECRETS, which, for the first time, estimates the individual treatment effect (ITE) per patient in the RCT study without using any external data by leveraging a state-of-the-art counterfactual estimation algorithm, called synthetic intervention. It also uses a new hypothesis testing strategy to determine whether the treatment has a clinically significant ATE based on the estimated ITEs. We show that SECRETS can improve the power of an RCT while maintaining comparable significance levels; in particular, on three real-world clinical RCTs (Phase-3 trials), SECRETS increases power over the baseline method by $\boldsymbol{6}$-$\boldsymbol{54\%}$ (average: 21.5%, standard deviation: 15.8%).

Summary

We haven't generated a summary for this paper yet.

List To Do Tasks Checklist Streamline Icon: https://streamlinehq.com

Collections

Sign up for free to add this paper to one or more collections.

Lightbulb On Streamline Icon: https://streamlinehq.com

Continue Learning

We haven't generated follow-up questions for this paper yet.